Docetaxel and considerably less harmful proteasome inhibitors. It remains to be established whether or not the therapeutic window of agents which includes tanespimycin, temsirolimus, sorafenib, enzastaurin or other smallmolecule inhibitors is favorable. Moreover, clinical trials are screening whether the preclinical promise of focused antibody treatment translates.
